Advancing Synthetic Data for Paradigm Shift in Medical Research with Daniel Blumenthal MDClone
Release Date: 08/14/2025
Developing Immunotherapy to Fight Bone Cancer with Paul Romness and Olivia Egge OS Therapies TRANSCRIPT
Empowered Patient Podcast
Paul Romness, Chairman, CEO, and President of OS Therapies, and Olivia Egge, a member of the Board of Directors of OS Therapies, discuss osteosarcoma, a rare and aggressive form of bone cancer that primarily affects teenagers. OS Therapies is developing an immunotherapy that utilizes a weakened form of the listeria bacteria to stimulate the immune system and prevent the spread of cancer cells to the lungs and brain. Olivia's experience as a patient has motivated her to advocate for better treatment options and join the board of OS Therapeutics. Paul explains, "So osteosarcoma is quite...
info_outline
Developing Immunotherapy to Fight Bone Cancer with Paul Romness and Olivia Egge OS Therapies
Empowered Patient Podcast
Paul Romness, Chairman, CEO, and President of OS Therapies, and Olivia Egge, a member of the Board of Directors of OS Therapies, discuss osteosarcoma, a rare and aggressive form of bone cancer that primarily affects teenagers. OS Therapies is developing an immunotherapy that utilizes a weakened form of the listeria bacteria to stimulate the immune system and prevent the spread of cancer cells to the lungs and brain. Olivia's experience as a patient has motivated her to advocate for better treatment options and join the board of OS Therapeutics. Paul explains, "So osteosarcoma is quite...
info_outline
New Inhibitor Drug Transforms Cancer Treatment Accessibility with Dan Schmitt Actuate Therapeutics TRANSCRIPT
Empowered Patient Podcast
Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option. Dan explains, "So, GSK-3β is a known...
info_outline
New Inhibitor Drug Transforms Cancer Treatment Accessibility with Dan Schmitt Actuate Therapeutics
Empowered Patient Podcast
Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option. Dan explains, "So, GSK-3β is a known...
info_outline
Democratizing Molecular Diagnostics Transforming Transplant Success with Andrea James iMDx TRANSCRIPT
Empowered Patient Podcast
Andrea James, Chief Financial Officer at iMDx, is focused on expanding access to innovative molecular diagnostic testing staring with a test for monitoring transplanted organ health. The test measures the donor-derived cell-free DNA which can indicate the need for drugs to target organ rejection before invasive procedures are required. The company is developing a kit-based version of the test that can be run by hospitals rather than relying on centralized labs, to increase access to this diagnostic and improve transplant outcomes. Andrea explains, "We changed our name on June 17th from...
info_outline
Democratizing Molecular Diagnostics Transforming Transplant Success with Andrea James iMDx
Empowered Patient Podcast
Andrea James, Chief Financial Officer at iMDx, is focused on expanding access to innovative molecular diagnostic testing staring with a test for monitoring transplanted organ health. The test measures the donor-derived cell-free DNA which can indicate the need for drugs to target organ rejection before invasive procedures are required. The company is developing a kit-based version of the test that can be run by hospitals rather than relying on centralized labs, to increase access to this diagnostic and improve transplant outcomes. Andrea explains, "We changed our name on June 17th from...
info_outline
Healthcare Financial Recovery Driven by Focus on People First with James Hereford Fairview Health Services TRANSCRIPT
Empowered Patient Podcast
James Hereford, President and CEO of Fairview Health Services, describes this Minnesota-based healthcare system's $600 million turnaround and the importance of focusing on people and processes, not just technology changes. Addressing staff shortages, quality of care, and patient experience led to finding a holistic approach that improved financial outcomes and changed the culture in a sustainable way. Investments have been made in community programs like food access and vaccination events, recognizing the impact of social determinants of health on patient outcomes. James explains, "When doing...
info_outline
Healthcare Financial Recovery Driven by Focus on People First with James Hereford Fairview Health Services
Empowered Patient Podcast
James Hereford, President and CEO of Fairview Health Services, describes this Minnesota-based healthcare system's $600 million turnaround and the importance of focusing on people and processes, not just technology changes. Addressing staff shortages, quality of care, and patient experience led to finding a holistic approach that improved financial outcomes and changed the culture in a sustainable way. Investments have been made in community programs like food access and vaccination events, recognizing the impact of social determinants of health on patient outcomes. James explains, "When doing...
info_outline
Innovative Homeostasis Focused Drugs to Treat Root Causes of Disease with Steve Butts Arrivo BioVentures TRANSCRIPT
Empowered Patient Podcast
teve Butts, Co-Founder and CEO of Arrivo BioVentures, is a biopharmaceutical company focused on developing therapies that target the root causes of disease rather than just treating the symptoms. Their drugs treat major depressive disorder and acute pancreatitis through novel epigenetic mechanisms of action. Sex-based differences were observed in clinical trials where the drug SP-624 showed efficacy in females but not in males, which could lead to a paradigm shift in how depression is treated in men and women. Steve explains, "We've evolved over time at Arrivo and with our previous companies....
info_outline
Innovative Homeostasis Focused Drugs to Treat Root Causes of Disease with Steve Butts Arrivo BioVentures
Empowered Patient Podcast
Steve Butts, Co-Founder and CEO of Arrivo BioVentures, is a biopharmaceutical company focused on developing therapies that target the root causes of disease rather than just treating the symptoms. Their drugs treat major depressive disorder and acute pancreatitis through novel epigenetic mechanisms of action. Sex-based differences were observed in clinical trials where the drug SP-624 showed efficacy in females but not in males, which could lead to a paradigm shift in how depression is treated in men and women. Steve explains, "We've evolved over time at Arrivo and with our previous...
info_outlineDaniel Blumenthal, VP of Strategy at MDClone, is building synthetic data models to mimic real patient data without the need to protect the identity of individuals. This type of data is being utilized in drug discovery and development, building predictive tools and new care models, and to better understand biases in clinical trials making them more representative. AI tools play an essential role in generating and validating synthetic data as well as integrating it into various processes and environments.
Daniel explains, "Synthetic data means different things to different people. So I definitely would want to start with sharing what it usually means to MDClone, which is creating data based on real populations of patients, real patient data. Learning from that real patient data, extracting essentially the statistics from that data, understanding the relevant patterns that exist inside that data, and then, based on the statistics alone, generating a brand-new set of data, a brand-new set of people, and the synthetic data that we generate."
"If you look at it, essentially with your naked eye, you wouldn't know it's not real people. It has the same structure, has the same content appearance, and yet, inside, synthetic data contains no real people. So very different from other approaches to protecting patient privacy, which take a patient data set and hash data, mask data, or remove information like IDs, names, or locations."
"Instead of taking that sort of approach, synthetic data actually generates a brand-new set of people, fake people, that in our case, as we build it, maintain the same statistical properties, such that any analysis you want to complete, you could accomplish using the synthetic dataset just as you would with the original dataset. That it will yield the same meaningful conclusions as the synthetic that it would with the original."
#MDClone #MedAI #AI #SyntheticData #DrugDevelopment #DrugDiscovery #ClinicalTrials #PatientPrivacy
